アスピリンの耐性があります
Graeme J Hankey1, John W Eikelboom
1Department of Neurology, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia.
Lancet (London, England)
|February 21, 2006
まとめ
アスピリンが血小板活性化を抑制できないアスピリン抵抗性により,心血管疾患のリスクが増加する可能性があります. その原因を理解し,検出することが,この状態を克服する鍵です.
科学分野:
- 心血管医学 心血管医学
- 薬理学 薬理学とは
背景:
- アスピリン耐性とは,アスピリンが血小板トロンボキサンA2の産生を十分に抑制できない状態を意味する.
- この抵抗は,心血管疾患のリスクの増加と関連しています.
- 実験室での検査は,血小板トロンボキサンA2の生産または機能を評価することによって,アスピリン耐性を検出することができます.
研究 の 目的:
- アスピリン抵抗性の原因と影響を調査する.
- アスピリン耐性を検出する方法を検討する.
- アスピリン耐性を克服するための戦略について議論する.
主な方法:
- アスピリン耐性に関する研究の文献レビュー.
- 不適切な投与量,薬物相互作用,遺伝的要因を含む潜在的な原因の分析.
- 血小板機能の診断のための検査検査の検査.
主要な成果:
- アスピリン抵抗性の複数の原因を特定した:不適切な投与量,薬物相互作用,遺伝的変異 (COX-1ポリモルフィズム),非血小板源からの血小板素生成の増加,および高血小板周轉.
- アスピリン耐性症は,特定の実験室での検査で検出できることを確認しました.
- アスピリン耐性度の上昇と,心血管疾患のリスクの増加との相関性を強調した.
結論:
- アスピリン耐性は,心血管疾患のリスクの増加に関連した重要な臨床問題です.
- 根本的な原因に対処し,適切な診断検査を使用することは,アスピリン抵抗性の管理に不可欠です.
- 将来の研究は,定義の精錬,診断の正確性の向上,治療介入の評価に焦点を当てなければならない.
関連する概念動画
Cross-reactivity
Overview
Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
Combined Effects of Drugs: Antagonism
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Tissue-Drug Binding: Localization of Drugs and its Significance
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine the...
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine the...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


